In one report, clonality of the two distinct tumor components was assessed by microdissection with subsequent genetic analysis for KRAS and TP53 gene mutation and showed the same genetic alterations in the carcinomatous and the sarcomatous components, strongly suggesting a common origin [8]. The gene discussed is KRAS; the disease is neoplasm.